Abstract
Alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate (AMPA)-antagonists (i.e., 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline [NBQX] and 6-(1-imidazolyl)-7-nitroquinoxaline-2,3(1H,4H)-dione [YM900]) have shown protective effects in different animal models of focal and global cerebral ischemia. We have developed a new highly selective and water-soluble AMPA antagonist (SPD 502). The compound is well-tolerated in rodents producing no liver or kidney pathology after doses up to 120 mg/kg. The aim of the present study was to evaluate whether SPD 502 was also neuroprotective in a focal cerebral ischemia model.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sager, T.N., Møller, A., Wätjen, F., Paulson, O.B., Drejer, J. (1999). SPD 502 (NS 1209), a New Selective AMPA Antagonist, Reduces the Infarct Size in Rats Following Permanent Occlusion of the Middle Cerebral Artery. In: Ito, U., Fieschi, C., Orzi, F., Kuroiwa, T., Klatzo, I. (eds) Maturation Phenomenon in Cerebral Ischemia III. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58602-6_42
Download citation
DOI: https://doi.org/10.1007/978-3-642-58602-6_42
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65023-2
Online ISBN: 978-3-642-58602-6
eBook Packages: Springer Book Archive